Calico targets longevity pathway with rare disease win

FDA Breakthrough Therapy Designation for fosigotifator highlights a mechanism that extends well beyond an ultra-rare childhood disorder. Calico Life Sciences has received US FDA Breakthrough Therapy Designation for fosigotifator, its investigational eIF2B activator for Vanishing White Matter (VWM) disease, an ultra-rare inherited leukodystrophy with no approved treatments [1]. The designation follows preliminary clinical evidence from […] The post Calico targets longevity pathway with rare disease win appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.